The prevention of colorectal cancer is a subject of increasing medical importance, and there have been a number of promising recent developments. This book examines in detail important aspects of the current status and future prospects for chemoprevention of colorectal tumors. Research into the mechanisms that lead from early colorectal adenoma to colorectal cancer is discussed. The role and modes of action of available drugs such as celecoxib and sulindac are described, and recent data from aspirin trials are analyzed. In addition, the possible impact of nutritional agents with anti-inflammatory properties is considered, and strategies applicable in those with a high level of genetic risk are evaluated. An important feature of the book is its holistic perspective, making it relevant for gastroenterologists, internists, general practitioners, oncologists, colorectal and gastroenterological surgeons, and public health practitioners.

What is chemoprevention today?- Mechanistic aspects in tumor development and progression of colorectal adenoma and carcinoma.- Mode of action of aspirin as a chemopreventive agent.- Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials.- COX-2 active agents in chemoprevention (includes aspirin, coxibs, and DFMO).- New potential developments in aspirin/NSAID derivatives.- Aspirin in CRC chemoprevention in the context of other chronic diseases.- Nutritional agents with anti-inflammatory properties in chemoprevention of colorectal adenoma and carcinoma.- Genetic risks for CRC and hereditary forms of CRC. Strategies for prevention in high risk population.